Document is current
Any future updates will be listed below
-
Authors
Munir, Talha https://orcid.org/0000-0002-2901-0769
Martinez-Calle, Nicolás
Xu, Sheng
Yang, Keri
Ge, Xiaoyun
Ali, Ayad K.
Mohseninejad, Leyla
Dobi, Balázs
Rakonczai, Pal
Ma, Han
Williams, Rhys
Aldairy, Wassim
Lamanna, Nicole
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03336333 at ClinicalTrials.govnct02242942 at ClinicalTrials.govDocuments that mention this clinical trial
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results
https://doi.org/10.1200/jco-25-00758
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
https://doi.org/10.1200/jco-24-02265
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
https://doi.org/10.1007/s40487-025-00380-0
Documents that mention this clinical trial
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
https://doi.org/10.1007/s40261-022-01172-4
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
https://doi.org/10.1007/s12325-022-02170-w
Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
https://doi.org/10.1007/s40487-025-00380-0
-
Funding
Funding for this research was provided by:
Nucleus Group
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 28 August 2025
First Online: 13 September 2025
Declarations
:
: Talha Munir—honoraria: BeOne Medicines Ltd., AstraZeneca, Sobi, Roche, Janssen, AbbVie, and Lilly; consultant: AbbVie, BeOne Medicines Ltd., Sobi, Alexion, Novartis, Janssen, AstraZeneca, Lilly, and Roche; research grants: Janssen and AbbVie; travel, accommodations, or expenses: Alexion, BeOne Medicines Ltd., AbbVie, Janssen, and AstraZeneca; and advisory board: AbbVie, BeOne Medicines Ltd., AstraZeneca, and Janssen. Nicolás Martinez-Calle—advisory board: AbbVie, AstraZeneca, BeOne Medicines Ltd., Takeda, and CLS Behring; and speaker and honoraria: AbbVie, AstraZeneca, Janssen, and BeOne Medicines Ltd. Sheng Xu, Keri Yang, Xiaoyun Ge, Ayad K. Ali, Leyla Mohseninejad, Han Ma, Rhys Williams, and Wassim Aldairy—employment and may own stock: BeOne Medicines Ltd. Balázs Dobi—research funding: BeOne Medicines Ltd. Pal Rakonczai—current affiliation: AstraZeneca; has nothing to disclose. Nicole Lamanna—consulting or advisory role: AbbVie, AstraZeneca, BeOne Medicines Ltd., Lilly, and Genmab; and research funding: AbbVie, AstraZeneca, BeOne Medicines Ltd., Lilly, Genmab, Genentech, MingSight, Octapharma, and Oncternal.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
